TNDM Stock Chart & Stats
$745.00
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$745.00 - $745.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$20.48B
Enterprise Value$1.48K
Total Cash (Recent Filing)$570.26M
Total Debt (Recent Filing)$734.74M
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Aug 06, 2026EPS Estimate
-5.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.40
Shares Outstanding68,529,090
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)9.53
Price to Sales (P/S)1.46
P/FCF Ratio-49.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$505.17Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)-11.89
Revenue Forecast (FY)$18.80B
TNDM FAQ
What was Tandem Diabetes Care’s price range in the past 12 months?
Tandem Diabetes Care lowest stock price was $745.00 and its highest was $745.00 in the past 12 months.
What is Tandem Diabetes Care’s market cap?
Tandem Diabetes Care’s market cap is $20.48B.
When is Tandem Diabetes Care’s upcoming earnings report date?
Tandem Diabetes Care’s upcoming earnings report date is Aug 06, 2026 which is in 9 days.
How were Tandem Diabetes Care’s earnings last quarter?
Tandem Diabetes Care released its earnings results on May 07, 2026. The company reported -$5.203 earnings per share for the quarter, beating the consensus estimate of -$7.752 by $2.549.
Is Tandem Diabetes Care overvalued?
According to Wall Street analysts Tandem Diabetes Care’s price is currently Undervalued.
Does Tandem Diabetes Care pay dividends?
Tandem Diabetes Care does not currently pay dividends.
What is Tandem Diabetes Care’s EPS estimate?
Tandem Diabetes Care’s EPS estimate is -5.62.
How many shares outstanding does Tandem Diabetes Care have?
Tandem Diabetes Care has 68,529,090 shares outstanding.
What happened to Tandem Diabetes Care’s price movement after its last earnings report?
Tandem Diabetes Care reported an EPS of -$5.203 in its last earnings report, beating expectations of -$7.752. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Tandem Diabetes Care?
Currently, no hedge funds are holding shares in MX:TNDM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tandem Diabetes Care Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$505.17 (― Downside)
$505.17 (― Downside)
Blogger Sentiment
Bullish
MX:TNDM Sentiment 70%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Negative
20 days / 200 days
Momentum
10.88%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
25.08%
Trailing 12-Months
Company Description
Tandem Diabetes Care
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
TNDM Company Deck
TNDM Earnings Call
Q1 2026
0:00 / 0:00
TNDM Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$505.17
Technical Analysis
1 Day
3 Days
1 Week
1 Month